Key Investor Signals
Completed a 75-participant urine-monitoring study
Amsterdam UMC completed the 75-participant Gravity of Flow study in March 2026. It included technical feasibility testing and a randomized comparison of automated versus manual monitoring.
Measured urine output with 2.3% median error
In a single-centre study of 23 analyzed cardiology patients, the monitor recorded 100% median hourly completeness and 2.3% median absolute volume error against a reference collection container.
Started a €1.5M joint urine-monitoring project
Flowsure and Amsterdam UMC began a project to develop urine-data alerts, supported through Health~Holland. The collaboration has a total budget of €1.5M.
Team
Tom Brouwer
CEO and Co-founder
- Earned a University of Amsterdam PhD in 2018 on defibrillators placed under the skin, with research on their clinical use.
- Trained in cardiology at Amsterdam UMC from 2018, following a research fellowship at its Academic Medical Center in 2014–2018.
- Worked in clinical research at Physio Control EMS systems in 2011–2013, gaining experience in emergency medical technology.
Gilmer Sussenbach
Co-founder
- Developed research devices at Amsterdam’s Academic Medical Center from 2011, combining embedded electronics, hardware and software.
- Designed and programmed a unit for transporting living liver cells, coordinating engineers and clinicians for transport to Scotland.
- Worked as an intensive-care and operating-room biomedical engineer at Amsterdam’s Academic Medical Center in 2006–2009.
Reinoud Knops
Co-founder
- Professor of cardiology at Amsterdam UMC, with expertise in cardiac electrophysiology and development of implanted rhythm devices.
- Led the international PRAETORIAN randomized controlled trial comparing defibrillator types, published in the New England Journal of Medicine in 2020.
- By 2021, had implanted over 150 leadless pacemakers and participated in the Nanostim and Micra first-in-human studies.
Product
Flowsure’s investigational monitor weighs a standard urine collection bag and converts changes in weight into urine-output measurements. Its reusable hardware sends readings to the electronic health record.
Continuous bag-weight sensing
A weight sensor follows changes in the urine collection bag to estimate output over time. The reusable monitor works with standard bags and has a rechargeable battery for use beside the hospital bed.
Automatic patient-record updates
The monitor transmits readings over Wi-Fi to the electronic health record through a hospital data interface. Continuous capture creates a time series for the care team without nurses entering each measurement.
Filtering movement during use
Embedded software filters movement-related noise from the weight signal. The system detects when the bag is detached and calculates the volume change after reattachment, accommodating patient movement.
Market Overview
Urine-output monitoring is a hospital equipment and software category serving catheterized patients in acute care. Manual measurement and charting remain common, while dedicated automated systems provide continuous data. The purchasing need combines reliable fluid-balance information with less nursing documentation.
Hospitals buy bedside monitors alongside drainage consumables and connections to their patient-record systems. Established suppliers already sell automated urine monitors; some charge separately for connectivity. Reusable equipment compatible with standard bags addresses the cost and workflow constraints of wider ward adoption.
Estimated global revenue in 2025 across catheter-based, patch and wearable urine-output monitoring systems.
US public-health guidance estimates that 15–25% of hospitalized patients receive a urinary catheter during their stay.
Median reporting delay in a 2021 study of 44 cardiac-surgery patients at one US intensive care unit.
Approximately 2.3 million hospital beds were available in the EU in 2024, across all care functions.
Comparable Outcomes
FlowSense
FlowSense developed URINFO, a system for accurate, continuous urine-output monitoring. Its products were sold in Europe, the United States, Israel and China. Baxter acquired FlowSense in 2013 for approximately $9.5 million
Interested in More Startups Like Flowsure?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.